CervoMed completes Phase 2a trial enrollment for rare frontotemporal dementia candidate
CervoMed (NASDAQ:CRVO), a clinical-stage biotechnology company focused on treating age-related brain disorders, announced today that it has finalized patient enrollment for its Phase 2a clinical trial evaluating its lead drug candidate, neflamapimod, in individuals with nonfluent variant primary progressive aphasia (nfvPPA).










